Aten Porus: Tackling pharma's rare challenges

Those afflicted by orphan diseases are rare; companies looking for orphan drugs are rarer still. Among them is Aten Porus that has found early success in this uncharted region of medical science

(A link to this page will be included in your message)


Email

Your Name
Required
Email Address
Required
 Send me a copy
Recipient's Email Address
Required
Separate multiple email addresses with commas (max 20)
Your Message
(1000 characters max)
"The details you provide on this page will not be used to send unsolicited e-mail, and will not be sold to a 3rd party."